Overview

A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)

Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety and efficacy for 52-week dosing of JR-131 in renal anemia patients with chronic kidney disease (CKD).
Phase:
Phase 3
Details
Lead Sponsor:
Kissei Pharmaceutical Co., Ltd.
Collaborators:
JCR Pharmaceutical Co., Ltd.
JCR Pharmaceuticals Co., Ltd.